Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.2%

Tyra Biosciences, Inc. (NASDAQ:TYRA) shares shot up 6.2% during mid-day trading on Monday . The stock traded as high as $16.98 and last traded at $16.98. 42,326 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 145,459 shares. The stock had previously closed at $15.99.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on TYRA. Oppenheimer reissued an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research report on Wednesday. Wedbush reissued an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Tyra Biosciences in a report on Wednesday.

Tyra Biosciences Trading Up 1.6 %

The stock has a market cap of $891.60 million, a P/E ratio of -10.10 and a beta of 1.01. The stock has a 50 day simple moving average of $17.62 and a 200 day simple moving average of $16.57.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Thursday, May 9th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.11. Equities analysts anticipate that Tyra Biosciences, Inc. will post -1.71 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In related news, COO Daniel Bensen sold 3,502 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $20.00, for a total value of $70,040.00. Following the completion of the transaction, the chief operating officer now owns 427,981 shares of the company’s stock, valued at approximately $8,559,620. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 15.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. lifted its holdings in shares of Tyra Biosciences by 43.9% in the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after buying an additional 3,180,155 shares in the last quarter. BVF Inc. IL boosted its holdings in shares of Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after purchasing an additional 1,921,599 shares in the last quarter. Kynam Capital Management LP bought a new position in shares of Tyra Biosciences during the 4th quarter valued at about $4,712,000. Vanguard Group Inc. increased its position in shares of Tyra Biosciences by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after purchasing an additional 140,833 shares during the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of Tyra Biosciences during the 1st quarter valued at about $977,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.